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Abstract
Diamond-Blackfan Anaemia (DBA) is a rare inherited anaemia caused by heterozygous
mutations in one of 13 ribosomal protein genes. Erythroid progenitors (BFU-E and CFU-E)
in bone marrow (BM) show a proapoptotic phenotype. Suspicion of DBA is reached after
exclusion of other forms of BM failure syndromes. To improve DBA diagnosis, which is con-
firmed by mutation analysis, we tested a new approach based on the study of extracellular
vesicles (EVs) isolated from plasma by differential centrifugations and analysed by flow
cytometry. We chose CD34, CD71 and CD235a markers to study erythroid EVs. We char-
acterised the EVs immunophentoypic profiles of 13 DBA patients, 22 healthy controls and
16 patients with other haematological diseases. Among the three EVs clusters we found,
only the CD34+/CD71low population showed statistically significant differences between
DBA patients and controls (p< 0.05). The absence of this cluster is in agreement with the
low levels of BFU-E found in DBA patients. The assessment of ROC curves demonstrated
the potential diagnostic value of this population. We suggest that this assay may be useful
to improve DBA diagnosis as a quicker and less invasive alternative to BM BFU-E culture
analysis.
Introduction
Diamond-Blackfan Anaemia (DBA, OMIM 105650) is a rare inherited pure red cell aplasia
that typically presents in the first year of life with an incidence of 6–7 newborns per million live
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births. Penetrance is incomplete and expressivity widely variable even in patients from the
same family. Patients with DBA exhibit a macrocytic normochromic anaemia and reticulocyto-
penia [1]. Approximately 40% of patients display additional clinical abnormalities such as cra-
niofacial, thumb, kidney and heart malformations and growth retardation [2]. Erythroid
progenitors (BFU-E and CFU-E) in the patients’ bone marrow (BM) show a pro-apoptotic
phenotype and their number is reduced in most patients. The erythrocyte adenosine deaminase
(eADA) activity is elevated in 80–85% of patients, but cannot be performed in transfused
patients [3].
DBA is considered as the prototype of ribosomopathies. Heterozygous mutations in one of
13 ribosomal protein (RP) genes have been found in about 65% of patients [4]. Haploinsuffi-
ciency of ribosomal proteins leads to ribosomal stress and activation of p53–dependent and
independent pathways, which result in apoptosis and decreased proliferation [5, 6, 7]. A non-
ribosomal form of DBA due to mutations in the GATA1 erythroid-specific transcription factor
has also been reported [8, 9].
During the course of the disease, approximately 17% of all DBA patients enter spontaneous
or steroid-induced remission, defined as a state of transfusion independence for at least six
months with physiologically acceptable haemoglobin levels. The mechanism behind remission
remains unknown and about 15% of those who enter remission relapse [3].
Diagnosis of DBA is hampered by the presence of other BM failure syndromes such as Fan-
coni Anaemia (FA), Shwachman-Diamond syndrome (SDS), Dyskeratosis Congenita (DC)
and Transient Erythroblastopenia of Childhood (TEC), which can have overlapping clinical
presentations [10]. FA is excluded from a diagnosis by negative results in a chromosome break-
age assay while the absence of telomere shortening rules out DC. SDS is characterised by pan-
creatic insufficiency and often associated with skeletal malformations and neutropenia.
The absence of a unique diagnostic feature for DBA often makes DBA a diagnosis of exclu-
sion. While the identification of the underlying molecular basis for DBA in many patients has
now made diagnosis possible through genetic testing, the genes affected in approximately 35%
of suspected DBA patients remain unknown leaving a degree of diagnostic uncertainty for
these patients. Further confounding a diagnosis of DBA is the increased identification through
genetic testing of patients with non-classical forms of DBA including patients with malforma-
tions without anaemia or with anaemia presenting as an adult. Recently, we have proposed a
rapid and convenient assay readily available in diagnostic laboratories where functional defects
in ribosome synthesis linked to haploinsufficiency for large subunit ribosomal proteins could
be used as a criterion for making a DBA diagnosis [4]. This approach is currently limited to
large subunit ribosomal proteins and would only be supportive by exclusion for DBA caused
by defects in non-ribosomal protein genes.
As an alternative strategy for developing a more inclusive assay for possible use in DBA
diagnosis we turned to the study of extracellular vesicles (EVs) whose presence may be altered
as a consequence of increased apoptosis associated with many bone marrow failures and whose
characteristic molecular properties may specifically define the nature of the bone marrow fail-
ure. EVs are membrane-bound organelles released by various cell types. Their membrane dis-
plays typical markers of the parental cell of origin. Microvesicles (MV) have a diameter of 50-
1000nm. MVs have not an endosomal origin and they are enclosed by plasma membrane frag-
ments [11;12]. The outer layer of MV membrane has been often shown to display phosphati-
dylserine (PS), but this may depend on the cell type from which MVs derive or on the
functional cell state [13]. Apoptotic bodies (ABs) are 1–5 μm in diameter. They are released as
blebs by cells undergoing apoptosis and they are PS positive.
MVs play a pivotal role in important biological processes such as membrane traffic and hor-
izontal transfer of proteins and nucleic acids among neighboring cells [14]. With regard to the
Erythroid EVs in DBA
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erythroid compartment, it is well known that mature red blood cells shed EVs during eryptosis
(a form of erythroid cellular stress) and that reticulocytes eliminate the nucleus and other cellu-
lar compartments through vesiculation [15]. No data are available on EV production from ery-
throid progenitors or early precursors. Classification of EVs, their isolation protocol and
detection, molecular details of their release, clearance and biological function are still under
intense investigation [16, 17].
In the present study we focused on the immunophenotypic characterization of erythroid
EVs from plasma of three different groups of individuals: DBA patients, patients with other
haematological diseases, and healthy controls. We reasoned that erythroid EVs may vary in the
peripheral blood of DBA patients as a consequence of the loss of erythroid progenitor cells in
the marrow of these patients. To our knowledge, this is the first attempt to use EVs in the
peripheral blood as an assay for marrow failure and to use EVs as a potential diagnostic tool for
Diamond-Blackfan Anaemia.
Three markers were used to characterise EVs derived from cells of the erythroid lineage:
CD34, CD71 and CD235a. CD34 is the main haematopoietic stem cell marker. CD71 is trans-
ferrin receptor 1, which is essential for iron uptake and consequently for haemoglobin synthe-
sis during erythroid differentiation (progenitors, i.e. BFU-E, CFU-E and early precursors, i.e
proerythroblast, basophilic erythroblast, polychromatophilic erythroblast and orthochromatic
erythroblast). Finally, CD235a, i.e. glycophorin A, is the erythroid specific marker and it is
expressed by erythroid precursors, i.e proerythroblast, basophilic erythroblast, polychromato-
philic erythroblast, orthochromatic erythroblast, reticulocytes and erythrocytes (Fig 1) [18, 19].
Additionally, the presence of PS (e.g a marker of ABs and certain MV types) was tested by
Annexin-V binding.
Methods
Ethical Statement
The ethical committee of Regina Margherita Children's Hospital (Turin) approved the use of
blood samples for diagnostic procedures. A written informed consent was signed by all the
individuals under study or their parents, caretakers, or guardians on behalf of the minors/
children.
Patients and controls
Peripheral blood samples were collected from DBA patients (n = 13) (Table 1), patients with
other haematological diseases (hereafter named non-DBA patients) (n = 16) (Table 2) and
healthy controls (n = 22) (S1 Table). For transfusion dependent patients, peripheral blood sam-
ples were collected after 2–5 weeks from the last transfusion, depending on their anaemia
severity.
EV enrichment
Blood samples were collected into 3.2% sodium citrate tubes. Platelet free plasma (PFP) was
obtained by a centrifugation at 2,400g for 10 minutes at room temperature. PFP was then cen-
trifuged at 1,800g for 30 minutes at 4°C. Supernatant was subjected to ultracentrifugation at
100,000g for 60 minutes at 4°C (OptimaTM LE-80K, Beckman Coulter; rotor SW60Ti, Beckman
Coulter). Pellets containing EVs were suspended in 1 mL of PBS (filtered using a 0.22 μm pore
size membrane) and stored at 4°C.
Erythroid EVs in DBA
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Fig 1. Simplified scheme of erythropoiesis. The most representative markers expressed during erythroid maturation steps are indicated. The intensity
colour variation corresponds to expression levels.
doi:10.1371/journal.pone.0138200.g001
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EV immunophenotypic profiles
100 μL of resuspended EVs were incubated for 15 minutes at 4°C in the dark with the following
combinations of antibodies: 1) anti-IgG2A-FITC/IgG1-PE (isotypic control); 2) anti-
CD71-FITC and anti-CD34-PE (this mixture was expected to identify vesicles from BFU-E to
ortochromatic erythroblast); 3) anti-CD71-FITC, anti-CD34-PerCP and anti-CD235a-PE (this
mixture was expected to identify vesicles from late progenitors to mature erythrocytes). After a
washing step with filtered PBS, EVs were resuspended in 400 μL of Annexin-V buffer and
2.5 μL of Annexin-V-APC were added to the mixes 2 and 3. All reagents for the immunophe-
notypic analysis were purchased from BD. A FACSCanto II flow cytometer (BD) with FacsDiva
software (BD) was used for data acquisition. Standard size micro beads of 1 and 2 μm (Flow
Cytometry Size Calibration Kit, Invitrogen) were used to calibrate the instrument. We have set
the EV dimensional gate to analyse events between 500 nm and 1000 nm. Gate positioning was
performed evaluating the median corresponding to 1000nm microbeads and exploiting the
direct proportionality between the scattered light and the dimension (Fig 2, upper left panel
and S2 Fig).
The relative amount of EVs per samples was determined using the TruCountTM tubes (BD),
according to the formula: (number of events in specific gate/ number of TruCount events) 
(number of TruCount beads per test/ test volume) dilution factor. Statistical analyses were
performed using Mann-Whitney and Kruskal-Wallis tests.
ROC curves
Receiver operating characteristic (ROC) curves were established to evaluate the potential diag-
nostic value of the EV analysis. In a ROC curve the true positive rate (Sensitivity) is plotted in
Table 2. Clinical characteristics of Non-DBA Patients.
NON-DBA
PATIENTS
SEX AGE TREATMENT Hb (g/
dL)
MCV
(fL)
RBC
(10^6/uL)
Reticulocytes
(10^9/L)
DISEASE
23 F 7 NONE 13.3 67.6 5.74 44.8 Heterozygous for Beta
Thalassemia
24 M 4 IRON 12.0 80.5 4.16 69.9 Iron deficiency anaemia
25 M 1 NONE 12.2 70.6 4.96 55.7 Heterozygosis for Hb S
26 M 5 NONE 9.0 62.3 4.45 47 Iron refractory anaemia
27 M 9 TRANSFUSION 9.9 88.0 2.98 33.5 Congenital dyserythropoietic
anemia type II (CDA II)
28 M 12 NONE 14.4 85.6 4.69 110.5 Spherocytosis (Splenectomized)
29 M 20 NONE 17.5 88.9 5.26 80.4 Acquired erytrocytosis
30 M 4 NONE 10.8 67.8 4.85 118.1 Iron deficiency anaemia
31 F 7
months
NONE 8.2 76.3 3.19 64.9 Homozygous for Beta thalassemia
32 M 15 CYCLOSPORIN,
STEROIDS
6.7 92.0 2.09 28.9 Aplastic anaemia
33 F 8 STEROIDS 9.9 85.4 3.4 44.7 Aplastic anaemia
34 F 14 NONE 9.1 85.0 3.19 56.4 Congenital dyserythropoietic
anemia type II (CDA II
35 M 10 NONE 13.0 95.3 3.86 82.1 Fanconi Anaemia
36 M 10 NONE 13.0 77.1 4.97 77.3 Lymphadenitis
37 M 12 NONE 13.4 75.4 4.88 N.D Thrombocytopenia
38 M 13 MYCOPHENOLATE 14.7 77.0 5.50 64.6 Autoimmune lymphoproliferative
syndrome (ALPS)
doi:10.1371/journal.pone.0138200.t002
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Fig 2. EV distribution in a dot plot graph comparing CD71 and CD34markers of the events occuring in the EV dimensional gate. CD71+/CD34-
(corresponding to CD71+/CD34-/CD235alow/PS-) and CD34+/CD71low (corresponding to CD34+/CD71low/CD235a+/PS+) populations are shown in
representative subjects (healthy controls, DBA patients and non-DBA patients). Comparison of EV populations obtained with or without CD235a staining is
shown.
doi:10.1371/journal.pone.0138200.g002
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function of the false positive rate (100-Specificity) for different cut-off points of a parameter.
The Area Under the ROC Curve (AUC) is a measure of the accuracy of a parameter in the dis-
crimination of two groups under study. An AUC of 1 represents an excellent test; an AUC of
0.5 represents a test that fails to discriminate between the two groups under study. A rough
guide for classifying the accuracy of a diagnostic test is the traditional academic point system:
90–100% = excellent, 80–90% = good, 70–80% = fair, 60–70% = poor, 50–60% = fail [20].
Results
EV immunophenotypic profile
The markers we used were chosen to identify EVs derived from early progenitors including
BFU-E (CD34, CD71), CFU-E (CD71), erythroid precursors (CD71, CD235a) and cells in the
late stage of erythroid maturation, i.e reticulocytes and erythrocytes (CD235a) (Fig 1). An iso-
typic control was used to set the gates of interest (S1 Fig). The immunophenotypic analysis was
performed on the events occurring only within the EV dimensional gate (Fig 2, upper panel
and S2 Fig).
S1 Fig shows EVs from healthy controls grouped into the following categories: EVs shed
from late erythroid progenitors (CD34+/CD71low/CD235alow/PS+), erythroid precursors
(CD71+/CD34-/CD235alow/PS-), and cells of late erythroid stages, e.g. reticulocytes and eryth-
rocytes (CD71-/CD235a+/CD34-. About 60% of this population was PS+). Since the anti-
CD235a-PE was prone to aggregation we evaluated whether the same EV populations could be
defined without using this antibody. Comparison of experiments with and without anti-
CD235a antibody showed that CD71+/CD34-/PS- and CD34+/CD71low/PS+ populations cor-
responded to the CD71+/CD34-/CD235alow/PS- and CD34+/CD71low/CD235alow/PS+ popula-
tions, respectively (vesicles obtained using or not the antibody against CD235, were counted
and their numbers corresponded) (Fig 2, and S2 Table). Consequently, we reasoned that the
mixture without CD235a was more suitable for diagnostic purposes because it was not influ-
enced by these technical concerns.
When we started this work PS was considered as the main marker of EVs. Current data
indicate that EVs populations derived from different cells may be PS+ or PS- [15]. In our
experiments, its presence was not helpful in the discrimination of EV population derived from
DBA patients compared to controls. When we tested DBA patients, only the CD34+/CD71low/
PS+ population (hereafter named CD34+/CD71low) was significantly different when compared
to other groups. This population, representing late erythroid progenitors was substantially
reduced in 8/13 DBA patients relative to healthy controls. Among patients with other haemato-
logical disorders, 15/16 patients showed a proportion of EVs derived from erythroid progeni-
tors similar to controls (Fig 2). The median difference between DBA patients and all the other
individuals (non-DBA patients + healthy controls) was statistically significant (p<0.05, Mann-
Whitney Test) as was the difference between DBA patients and each of the other groups when
compared separately (p<0.05, Kruskal-Wallis Test; Fig 3). As expected, the difference of medi-
ans comparing non-DBA patients vs healthy controls was not statistically significant (Fig 3).
Finally the CD71-/CD34-/CD235a+ EV population, that is shed from the late stage of matu-
ration, represents the bulk of events. It should be noted that in all transfusion dependent
patients, either DBA or non-DBA, this population includes also EVs shed from donor cells.
Consequently, we could not compare this population among the three groups analysed.
ROC curves
The assessment of Receiver Operating Characteristic (ROC) curves demonstrated the potential
use of the CD34+/CD71low population as a diagnostic tool. The area under the ROC curve
Erythroid EVs in DBA
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(AUC) that compares DBA patients vs healthy controls was 0.84 (= good) while the AUC of
DBA patients vs all the other individuals was 0.80 (= good). Moreover, comparison between
DBA patients and non-DBA patients produced an AUC of 0.75 (= fair). In all comparisons the
cluster was able to distinguish the groups under study with a p-value< 0.01. As expected the
AUC that plotted non-DBA patients and healthy controls was 0.66 (= poor), consequently this
assay cannot discriminate between these groups (Fig 4).
Discussion
The aim of this study was to evaluate if EV populations in the peripheral blood of DBA patients
can be leveraged as a potential diagnostic tool. We studied EVs by flow cytometry, which pro-
vides information both on vesicle dimensions and immunophenotypic properties. Vesicles in
the size range of 500nm to 1000nm were used in this study. This size range includes a heteroge-
neous population of EVs including both microvesicles and relatively small apoptotic bodies.
Using our approach we were able to identify EVs ranging from early erythroid progenitors
to mature erythrocytes. The bulk of these EVs are likely derived from the peripheral blood,
because if the detected EVs derived also from bone marrow EV populations, vesicles derived
from all types of erythroid progenitors and precursors would be expected.
Importantly, of the vesicle populations studied, the CD34+/CD71low cluster showed statisti-
cally significant differences between DBA patients and healthy controls or patients with other
haematological diseases (Fig 3).
The potential diagnostic value of the analysis of CD34+/CD71low EVs was assessed using
the ROC curve test. AUC values suggest that this test has a good accuracy to discriminate DBA
Fig 3. Box plot of Absolute number of events included in the CD34+/CD71low gate.Outliers are shown in black spots. Comparison between DBA
patients, non-DBA patients and healthy controls. *The difference of medians is statistically significant (p<0.05, Kruskall-Wallis test).
doi:10.1371/journal.pone.0138200.g003
Erythroid EVs in DBA
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patients from healthy controls, and/or from non-DBA patients. The CD34+/CD71low EV pop-
ulation is expected to be shed from BFU-E progenitors and our results are in agreement with
the low levels of BFU-E found in DBA patients (Table 1).
Actually, this population seems to reflect more the bone marrow BFU-E numbers than the
level of anaemia or the disease type. According to this hypothesis, 3 DBA patients (#7, #10,
#12), who show this population, had normal erythropoiesis at the time of this analysis
(Table 1). In contrast, we found a single DBA patient (#11) with anaemia at the time of this
analysis who showed normal levels of this EV population without an evident explanation.
On the other hand, all but one patient with other haematological diseases clustered in the
healthy control range. This cluster includes six patients with congenital anaemias characterised
by erythroid cell loss at a stage that is later than BFU-E (i.e. HbS, spherocytosis, CDA II and
Beta thalassemia), and five patients with acquired conditions. We also analysed a patient with
Fanconi Anaemia which can have overlapping features with DBA.
Fig 4. ROC curves analysis of CD34+/CD71low population. ROC curves evaluating the accuracy (AUC) of the CD34+/CD71low analysis in the
discrimination of (A)DBA patients vs healthy controls (B) DBA patients vs all the others (healthy controls + non-DBA patients) (C) DBA patients vs non-DBA
patients (D) non-DBA patients vs healthy controls. * p-value <0.01.
doi:10.1371/journal.pone.0138200.g004
Erythroid EVs in DBA
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Patient #26 is the only non-DBA patient who did not show this population. He is affected
by an iron refractory anaemia with severe microcytosis. We expect that this patient also has a
defect of erythroid progenitors, but a BM evaluation has not been performed so far.
Overall these data suggest that the EV assay we devised may be useful to improve DBA diag-
nosis as a quicker and less invasive alternative to BFU-E cultures. It should be noted that this
assay is performed from peripheral blood, is amenable to transfused patients and requires only
two working days, whereas BFU-E cultures require 15 working days and needs to be performed
using a bone marrow sample in DBA patients.
Finally, this assay could be a useful tool to select erythroid cell-derived EVs in order to study
their content and their functional role in erythroid differentiation. It may also be modified to
isolate EVs derived by other lineage specific progenitors and used to study other types of bone
marrow failure syndromes.
Supporting Information
S1 Fig. EV distribution in dot plot graphs obtained from the acquisition of the samples
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were identified and indicated with different colours.
(TIF)
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(TIF)
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formed on the same control or patient in two independent samples).
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